SCHEDULE 13D/A: 180 Life Sciences CEO Blair Jordan Boosts Stake to 31.7% Amid Accelerated Vesting and New Equity Grants

Blair Jordan, CEO of 180 Life Sciences Corp., has significantly increased his beneficial ownership to 31.7% through accelerated restricted stock vesting, new option and restricted stock grants, and strategic voting agreements.

Summary

• Blair Jordan, the Chief Executive Officer of 180 Life Sciences Corp., has increased his beneficial ownership in the company to 1,900,812 shares, representing 31.7% of the common stock outstanding as of April 19, 2025.
• This increase is primarily due to the accelerated vesting of 160,000 restricted shares on June 17, 2025, which were originally scheduled to vest in two tranches on January 1, 2026, and December 31, 2026.
• Mr. Jordan also received new equity grants on June 17, 2025, including options to purchase 410,000 shares of common stock at an exercise price of $0.9290 per share, and 179,646 shares of restricted common stock.
• The options and new restricted stock grants will vest in two equal tranches on the six and twelve-month anniversaries of the grant date.
• A significant portion of Mr. Jordan's beneficial ownership stems from irrevocable voting proxies obtained through voting agreements with Dr. James Woody (43,166 shares), Dr. Marlene Krauss (200,000 shares), and Elray Resources, Inc. (1,318,000 shares), granting him shared voting power over these shares.
• The 2025 Option Incentive Plan, under which the 410,000 options were granted, has been approved by the Board of Directors but requires stockholder approval before options can be exercised.
• Mr. Jordan holds 160,000 shares with sole voting and dispositive power, and 1,740,812 shares with shared voting power, but no dispositive power over the shares subject to voting proxies.

Sentiment

Score: 7

Explanation: The document indicates increased alignment between the CEO and shareholders through significant beneficial ownership and new equity grants, including accelerated vesting. There are no negative financial or operational disclosures, though a risk related to stockholder approval for new options is noted.

Positives

• Blair Jordan's beneficial ownership increased to 31.7%, aligning management interests with shareholders.
• 160,000 restricted shares granted to Mr. Jordan in February 2025 had their vesting accelerated to June 17, 2025, providing immediate ownership.
• Mr. Jordan was granted new options to purchase 410,000 shares and 179,646 restricted shares, demonstrating continued commitment to executive compensation and retention.

Risks

• The 2025 Option Incentive Plan, under which 410,000 options were granted, requires stockholder approval; if not obtained, the plan can be unwound and outstanding options cancelled.
• The voting agreements with Dr. James Woody, Dr. Marlene Krauss, and Elray Resources, Inc. are temporary and will expire on specific dates (February 5, 2026, August 21, 2025, and April 28, 2026, respectively), potentially reducing Mr. Jordan's shared voting power.

Future Outlook

The Reporting Person acquired the securities for investment purposes and may purchase additional securities or dispose of current holdings in the future, depending on market conditions. He may also acquire additional shares under future employee benefit and compensation arrangements. The Reporting Person does not currently have plans for extraordinary corporate transactions, changes in management or board, or material changes to capitalization or dividend policy, but retains the right to modify his plans.

Management Comments

• "The Reporting Person acquired the securities for investment purposes."
• "The Reporting Person retains the right to change his investment intent, and may, from time to time, acquire additional shares of Common Stock or other securities of the Company, or sell or otherwise dispose of (or enter into a plan or arrangements to sell or otherwise dispose of), all or part of the shares of Common Stock or other securities of the Company, if any, beneficially owned by him, in any manner permitted by law."
• "The Reporting Person, in his capacity as a member of the Board and Chief Executive Officer may, from time to time, become aware of, initiate, and/or be involved in discussions that relate to the transactions described in this Item 4 and thus retains his right to modify his plans with respect to the transactions described in this Item 4 to acquire or dispose of securities of the Company and to formulate plans and proposals that could result in the occurrence of any such events, subject to applicable laws and regulations."

Industry Context

This document is a specific disclosure of an executive's beneficial ownership and compensation structure within 180 Life Sciences Corp. It does not provide broader industry trends or competitive analysis.

Corporate Governance

Related Party Transactions

• Executive Consulting Agreement between the Issuer and Blair Jordan Strategy and Finance Consulting Inc. (an entity owned by Mr. Jordan) dated February 21, 2025.
• Grant of 160,000 restricted shares to Mr. Jordan under the Issuer's 2022 Omnibus Incentive Plan.
• Accelerated vesting of 160,000 restricted shares for Mr. Jordan.
• Grant of options to purchase 410,000 shares of common stock to Blair Jordan Strategy and Finance Consulting Inc. (owned and controlled by Mr. Jordan) under the 2025 Option Incentive Plan.
• Grant of 179,646 shares of restricted common stock to Blair Jordan Strategy and Finance Consulting Inc. (owned and controlled by Mr. Jordan) under the 2022 Omnibus Incentive Plan.

Stakeholder Impact

• Shareholders: Increased beneficial ownership by the CEO may signal confidence and align interests, but new equity grants could lead to potential dilution.
• Employees: The CEO's compensation structure and equity grants set a precedent for executive incentives.
• Board of Directors: Demonstrates active governance in executive compensation and equity plan management.

Next Steps

• The 2025 Option Incentive Plan, under which 410,000 options were granted, requires stockholder approval before options can be exercised.

Key Dates

Keywords

SEC filing, Schedule 13D, beneficial ownership, restricted stock, stock options, voting agreement, executive compensation, corporate governance, 180 Life Sciences Corp., Blair Jordan